BioArctic Teams Up With Mesenkia Therapeutics on Brain Cancer Treatment Option

MT Newswires · 2d ago
06:25 AM EDT, 08/19/2026 (MT Newswires) -- BioArctic (BIOA-B.ST) partnered with Mesenkia Therapeutics to look for an antibody-based treatment for glioblastoma, an aggressive and treatment-resistant form of brain cancer. Under the collaboration, the Swedish biopharmaceutical company will be in charge of developing a drug candidate through the combination of its BrainTransporter technology with Mesenkia's antibody, according to a Wednesday release. Both parties expect to validate their idea in preclinical studies, the results of which will determine the path ahead.